Nantahala Capital Management LLC Trims Stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Nantahala Capital Management LLC lowered its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 0.1% during the second quarter, according to its most recent filing with the SEC. The firm owned 2,512,850 shares of the company’s stock after selling 1,712 shares during the period. Establishment Labs accounts for approximately 6.7% of Nantahala Capital Management LLC’s portfolio, making the stock its 2nd largest position. Nantahala Capital Management LLC owned 9.13% of Establishment Labs worth $114,184,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Hood River Capital Management LLC bought a new stake in Establishment Labs during the second quarter valued at $43,000. Nkcfo LLC bought a new stake in shares of Establishment Labs in the 2nd quarter valued at $227,000. Concurrent Investment Advisors LLC acquired a new position in shares of Establishment Labs during the 1st quarter valued at $263,000. SG Americas Securities LLC bought a new stake in Establishment Labs in the second quarter valued at $303,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in shares of Establishment Labs during the second quarter valued at about $373,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Establishment Labs

In other news, CEO Quiros Juan Jose Chacon sold 3,866 shares of the company’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $45.01, for a total transaction of $174,008.66. Following the transaction, the chief executive officer now owns 215,030 shares of the company’s stock, valued at approximately $9,678,500.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 11.44% of the company’s stock.

Establishment Labs Trading Down 8.0 %

NASDAQ:ESTA opened at $43.27 on Tuesday. Establishment Labs Holdings Inc. has a 52 week low of $16.96 and a 52 week high of $60.12. The firm has a 50-day moving average price of $43.10 and a two-hundred day moving average price of $47.31. The company has a debt-to-equity ratio of 4.30, a quick ratio of 2.91 and a current ratio of 4.44. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -13.78 and a beta of 1.20.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). The business had revenue of $44.12 million during the quarter, compared to the consensus estimate of $43.10 million. Establishment Labs had a negative net margin of 54.97% and a negative return on equity of 220.67%. The firm’s revenue for the quarter was down 9.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.65) EPS. On average, equities analysts expect that Establishment Labs Holdings Inc. will post -2.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Mizuho increased their price target on Establishment Labs from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, June 6th. JPMorgan Chase & Co. reduced their price objective on shares of Establishment Labs from $61.00 to $50.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. Stephens reiterated an “overweight” rating and set a $68.00 price target on shares of Establishment Labs in a research note on Wednesday, August 7th. Finally, Citigroup raised their target price on Establishment Labs from $41.00 to $45.00 and gave the company a “neutral” rating in a report on Thursday, August 22nd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $56.60.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.